CHE vs SYRE
Chemed Corp. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
68
Buy
| Metric | CHE | SYRE |
|---|
| AI Score |
64
|
68
|
| Price |
$541.60
|
$104.13
|
| P/E Ratio |
26.96×
|
-52.69×
|
| ROE |
27.1%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.4%
|
0.0%
|
| Debt / Equity |
0.35×
|
0.00×
|
| Dividend Yield |
0.4%
|
0.0%
|
| RSI (14) |
53.7
|
53.3
|
| Beta |
0.511
|
3.026
|
| Expected Upside |
+0.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for CHE versus SYRE.
SYRE leads by 4 points.
SYRE scores 68/100 (Buy) versus CHE at 64/100 (Buy).
CHE Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 26.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.4% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 26.2 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical